[ad_1]
Novartis AG mentioned Monday that a demo analyzing breast-most cancers drug Kisqali satisfied its key endpoint through an interim examination.
The drug is revealed to noticeably minimize the hazard of illness recurrence when employed collectively with an endocrine remedy in individuals with sure kinds of early breast cancers at threat of recurrence, the company said.
The Section 3 demo, named Natalee, was stopped early as the most important endpoint has been achieved, Novartis
NOVN,
NOVN,
said.
Generate to Cecilia Butini at [email protected]
[ad_2]
Resource website link